The global tuberculosis situation: Progress and problems in the 20th century, prospects for the 21st century

Infectious Disease Clinics of North America

Volumn 16, Issue 1, 2002, Pages 1-58

  Cegielski, J Peter ^a,f   Chin, Daniel P ^b   Espinal, Marcos A ^b   Frieden, Thomas R ^a,b   Cruz, Rodolfo Rodriguez ^c   Talbot, Elizabeth A ^a,d   Weil, Diana E C ^e   Zaleskis, Richard ^b   Raviglione, Mario C ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c PAN AMERICAN HEALTH ORGANIZATION   (United States)

^d BOTUSA Project   (Botswana)

^e WORLD BANK   (United States)

^f World Bank ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; CHILD; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUCED DISEASE; EPIDEMIC; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; REVIEW; SKIN TOXICITY; TREATMENT FAILURE; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

EID: 0036121999     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(03)00045-X     Document Type: Review

References (196)

1. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: An operational assessment at a voluntary counseling and testing center
2. A prospective study of tuberculosis and human immunodeficiency virus infection: Clinical manifestations and factors associated with survival
3. Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998
4. Risk factors for tuberculosis in HIV infected persons: A prospective cohort study
5. DNA microarrays and combinatorial chemical libraries: Tools for the drug discovery pipeline
6. The history of tuberculosis as a global epidemic
7. Outbreak of multidrug-resistant tuberculosis infections in a hospital transmission to patients with HIV infection and staff
8. Comparative genomics of BCG vaccines by whole-genome DNA microarray
9. The role of fluoroquinolones in tuberculosis today
10. The intrinsic transmission dynamics of tuberculosis epidemics
11. Control strategies for tuberculosis epidemics: New models for old problems
12. Drug-resistant tuberculosis in Northern Germany: A retrospective hospital-based study of 1055 patients from 1984 until 1993
13. Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis
14. National trends in the concurrence of tuberculosis and acquired immunodeficiency syndrome
15. Impact of HIV on tuberculosis in sub-Saharan Africa: A regional perspective
16. Epidemiology of tuberculosis in the United States, 1985 through 1992
17. Tuberculous pericarditis in Tanzanian patients with and without HIV infection
18. Drug-susceptible tuberculosis outbreak in a state correctional facility housing HIV-infected inmates - South Carolina, 1999-2000
19. Estimates of global tuberculosis morbidity and mortality
20. Evaluation of a directly observed therapy short-course strategy for treating tuberculosis - Orel Oblast, Russian Federation, 1999-2000
21. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons - Florida and New York, 1988-1991
22. Preventing and controlling tuberculosis along the US-Mexico border
23. Primary multidrug-resistant tuberculosis - Ivanovo Oblast, Russia, 1999
24. Tuberculosis and the acquired immunodeficiency syndrome - New York City
25. Tuberculosis outbreaks in prison housing units for HIV-infected inmates - California, 1995-1996
26. Tuberculosis treatment interruptions - Ivanovo Oblast, Russian Federation, 1999-2000
27. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection
28. DOTS and drug resistance: A silver lining to a darkening cloud
29. Unusual pulmonary manifestations of disseminated Penicillium marneffei infection in three AIDS patients
30. Results of directly-observed short-course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis
31. Ten years of the National Tuberculosis/Leprosy Programme in Tanzania
32. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993
33. Drug resistance in tuberculosis: Review of the worldwide situation and WHO/IUATLD global surveillance project
34. The use of restriction fragment length polymorphism (RFLP) analysis for epidemiological studies of tuberculosis in developing countries
35. First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons
36. Streptomycin resistance in pulmonary tuberculosis
37. Pulmonary complications of human immunodeficiency virus infection in Dar es Salaam, Tanzania: Role of bronchoscopy and bronchoalveolar lavage
38. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus
39. Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme
40. Tuberculosis and HIV infection in sub-Saharan Africa
41. Mycobacterium tuberculosis in the postgenomic age
42. Tuberculosis in Siberia: Diagnosis, chemoprophylaxis and treatment
43. Tuberculosis in Siberia: An epidemiological and microbiological assessment
44. Severe cutaneous hypersensitivity reactions during treatment of tuberculosis in patients with HIV infection in Tanzania
45. Infection due to Penicillium marneffei, an emerging pathogen: Review of 155 reported cases
46. Prospects for worldwide tuberculosis control under the WHO DOTS strategy
47. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country
48. Evaluating the impact of tuberculosis control: Number of deaths prevented by short-course chemotherapy in China
49. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome
50. The impact of HIV on infectiousness of pulmonary tuberculosis: A community study in Zambia
51. Negative sputum smear results in HIV-positive patients with pulmonary tuberculosis in Lusaka, Zambia
52. Review: The immune response in human tuberculosis - Implications for tuberculosis control
53. Tuberculosis control in low-income countries
54. The global epidemiology of tuberculosis
55. Rational DOTS Plus for the control of multidrug-resistant tuberculosis
56. Standard short-course chemotherapy for drug-resistant tuberculosis. Treatment outcomes in 6 countries
57. Global trends in resistance to antituberculosis drugs
58. Infectiousness of Mycobacterium tuberculosis in HIV-1-infected patients with tuberculosis: A prospective study
59. The dilemma of MDR TB in the global era
60. Management of MDR-TB in resource-poor countries
61. Community-based approaches to the control of multidrug-resistant tuberculosis: Introducing DOTS-PLUS
62. Primary resistance examination in pulmonary tuberculosis cases in Budapest
63. Tuberculosis in New York City - Turning the tide
64. Clinical consequences and transmissibility of drug-resistant TB in Southern Mexico
65. Fluoroquinolones: A new treatment for tuberculosis?
66. Antituberculosis initial drug resistance of Mycobacterium tuberculosis in Kenya: A 10-year review
67. Microbial pathogenesis of Mycobacterium tuberculosis: Dawn of a discipline
68. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin
69. Recruitment to a trial of tuberculosis preventive therapy from a voluntary HIV testing center in Lusaka: Relevance to implementation
70. Rhodococcus equi and HIV-1 infection in Uganda
71. The arcana of tuberculosis
72. A prospective study of the risk of tuberculosis among HIV-infected patients
73. Responding to market failures in tuberculosis: A model to increase access to drugs and treatment
74. Isoniazid preventive therapy for tuberculosis in HIV-1 infected adults: Results of a randomized controlled trial
75. Low failure rate in standardized retreatment of tuberculosis in Nicaragua: Patient category, drug resistance and survival of chronic patients
76. Detection of Mycobacterium tuberculosis by molecular methods
77. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection
78. Two-year followup of persons with HIV-1 and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa
79. The nature and consequence of genetic variability within Mycobacterium tuberculosis
80. CD4 T lymphocyte count and the radiographic presentation of pulmonary TB
81. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus coepidemics in Botswana
82. Immigration and tuberculosis among children on the United States-Mexico border, County of San Diego, California
83. The status and prospects of tuberculosis control in India
84. Inadequacy of the current WHO retreatment regimen in a central Siberian prison: Treatment failure and MDR-TB
85. Use of mycobacterial smears in the diagnosis of pulmonary tuberculosis in AIDS/ARC patients
86. Clinical and programmatic mismanagement rather than community outbreak as the cause of chronic, drug-resistant tuberculosis in Buenaventura, Colombia, 1998
87. A random sample survey of initial drug resistance among tuberculosis cases in Latin America
88. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Laboratory Network: First round of proficiency testing
89. Molecular and conventional epidemiology of Mycobacterium tuberculosis in Botswana: A population-based study of 301 pulmonary tuberculosis patients
90. The impact of HIV on the usefulness of sputum smears for the diagnosis of tuberculosis
91. What we can learn from the Mycobacterium tuberculosis genome sequencing projects?
92. Incidence of tuberculosis in the United States among HIV-infected patients
93. Cost-effectiveness analysis of different policies of tuberculosis control in Ivanovo Oblast, Russian Federation
94. Delayed type hypersensitivity skin testing in Tanzanian adults with HIV infection
95. Risk for developing tuberculosis among anergic patients infected with HIV
96. Radiologic features of Rhodococcus equi pneumonia in AIDS
97. Modeling the impact of global tuberculosis control strategies
98. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients
99. Public-private partnership for tuberculosis control: Experience in Hyderabad, India
100. Twice weekly tuberculosis preventative therapy in HIV infection in Zambia
101. Significance of patient with x-ray evidence of active tuberculosis not bacteriologically confirmed
102. Risk factors for HIV infection among young adult men in northern Thailand
103. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya: Analysis of early (6-month) mortality
104. Rhodococcus equi infection: A cause of cavitary pulmonary disease in immunocompromised patients
105. Randomized trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans
106. Global surveillance for antituberculosis-drug resistance, 1994-1997
107. An overview on drug resistant tuberculosis in India
108. Variation in chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression
109. Pulmonary tuberculosis in HIV-infected patients in Zaire: A controlled trial of treatment for either 6 or 12 months
110. The radiographic appearance of tuberculosis in patients with acquired immune deficiency syndrome (AIDS) and pre-AIDS
111. Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in general population of the former Soviet Union
112. AIDS in Africa: An epidemiologic paradigm
113. Socio-economic impact of tuberculosis on patients and family in India
114. Tuberculosis trends in Eastern Europe and former USSR
115. Global epidemiology of tuberculosis: Morbidity and mortality of a worldwide epidemic
116. Secular trends of tuberculosis in western Europe
117. Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires
118. The mutual assistance program of the IUATLD: Development, contribution and significance
119. The International Tuberculosis Surveillance Research Unit (TSRU): The first 30 years
120. Drug resistance of M. tuberculosis
121. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection
122. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection
123. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy
124. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-crystallin
125. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection
126. Drug-resistant strains of Mycobacterium tuberculosis isolated in Russia
127. Overview and epidemiologic assessment of the current global tuberculosis situation with an emphasis on control in developing countries
128. The epidemiology of tuberculosis
129. Estimations concerning the world incidence of positive pulmonary tuberculosis from sputum smears. Unreliability of official totals reported on tuberculosis
130. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru
131. Tuberculosis among European patients with the acquired immune deficiency syndrome
132. Tuberculosis: A global overview of the situation today
133. Control of drug resistant TB, Botswana, 1999
134. Tuberculosis control in the era of the HIV epidemic: Risk of tuberculosis infection in Tanzania, 1983-1998
135. Results from 8 years of susceptibility testing of clinical Mycobacterium tuberculosis isolates in Denmark
136. The proportion of tuberculosis cases in Tanzania attributable to human immunodeficiency virus
137. Molecular epidemiology of tuberculosis and other mycobacterial infections: Main methodologies and achievements
138. Directly observed therapy and treatment adherence
139. Effectiveness of the direct observation component of DOTS for tuberculosis: A randomized controlled trial in Pakistan
140. Strengthening tuberculosis control within reforming health systems
141. A study of tuberculosis among foreign-born Hispanic persons in the US states bordering Mexico
142. The epidemiology of HIV infection and AIDS in Thailand
143. Tuberculosis drug resistance in the Western Cape
144. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus
145. Preventive therapy against tuberculosis in people living with HIV
146. Tuberculosis trends in Central and Eastern Europe and countries of the former USSR
147. Guidelines for surveillance of drug resistance in tuberculosis
148. HIV/AIDS revised 1999 estimates
149. Molecular epidemiology and transmission of Mycobacterium tuberculosis in rural Africa
150. Effect of preventive treatment for tuberculosis in adults infected with HIV: Systematic review of randomized placebo controlled trials
151. Molecular methods in the detection and identification of mycobacterial infections
152. Rapid increase in HIV-related tuberculosis, Chiang Rai, Thailand, 1990-1994
153. Tuberculosis control in the central Asian republics
154. Tuberculosis and its Control in the former Soviet Union
155. Tuberculosis control in the Caucasus: Successes and constraints in DOTS implementation
156. DOTS implementation in the Central Asian Republics
157. The epidemiology of tuberculosis in Latvia
158. Trend of initial drug resistance of tubercle bacilli isolated from new patients with pulmonary tuberculosis and its correlation with the tuberculosis programme in Beijing
159. Randomized controlled trial of self-supervised and directly observed treatment of tuberculosis